Search - tctmd.com

Displaying 281 - 300 of 345

Sort: Relevancy | Date

Absorb in Europe: When, How, and by Whom the Beleaguered BVS Is Being Used After Restrictions

News Features

Absorb in Europe: When, How, and by Whom the Beleaguered BVS Is Being Used After Restrictions

Michael O'Riordan

May 08, 2017

More Excess Bleeding and No Benefit With Triple Therapy After PCI, Meta-analysis Finds

News Daily News

More Excess Bleeding and No Benefit With Triple Therapy After PCI, Meta-analysis Finds

May 05, 2017

TCTMD’s Top 10 Most Popular Stories for April 2017

News Daily News

TCTMD’s Top 10 Most Popular Stories for April 2017

April 28, 2017

‘Forgotten’ Patients With Mechanical Heart Valves Undergoing PCI Pose Clinical Conundrum

News Daily News

‘Forgotten’ Patients With Mechanical Heart Valves Undergoing PCI Pose Clinical Conundrum

April 27, 2017

Incident MI and Very Late Stent Thrombosis in Outpatients With Stable CAD

Presentation

Incident MI and Very Late Stent Thrombosis in Outpatients With Stable CAD

April 25, 2017

Long-term MI Risk Among Stable CAD Patients: Some Clues From CORONOR

News Daily News

Long-term MI Risk Among Stable CAD Patients: Some Clues From CORONOR

April 24, 2017

Absorb Comparable to Xience in Economic Analysis, but BVS Safety Concerns Could Alter Balance

News Daily News

Absorb Comparable to Xience in Economic Analysis, but BVS Safety Concerns Could Alter Balance

Michael O'Riordan

April 18, 2017

Monthly Vitamin D Fails to Prevent CVD in Large Randomized Trial

News Daily News

Monthly Vitamin D Fails to Prevent CVD in Large Randomized Trial

April 07, 2017

Leaflet Thrombosis Common After Aortic Valve Implant, More So in TAVR Than in Surgery

News Conference News ACC 2017

Leaflet Thrombosis Common After Aortic Valve Implant, More So in TAVR Than in Surgery

Michael O'Riordan

March 19, 2017

ABSORB III: Two-Year Results Show a Higher MACE Rate Compared With Xience

News Conference News ACC 2017

ABSORB III: Two-Year Results Show a Higher MACE Rate Compared With Xience

Michael O'Riordan

March 18, 2017

FDA Warns of Risk of Major Adverse Cardiac Events With Absorb BVS

News Conference News ACC 2017

FDA Warns of Risk of Major Adverse Cardiac Events With Absorb BVS

Michael O'Riordan

March 18, 2017

Replacing Aspirin With Low-Dose Rivaroxaban for Post-ACS Therapy Appears Safe

News Conference News ACC 2017

Replacing Aspirin With Low-Dose Rivaroxaban for Post-ACS Therapy Appears Safe

March 18, 2017

Rivaroxaban Bests Aspirin for Preventing Recurrence of VTE: EINSTEIN CHOICE

News Conference News ACC 2017

Rivaroxaban Bests Aspirin for Preventing Recurrence of VTE: EINSTEIN CHOICE

March 18, 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

News Conference News ACC 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

March 10, 2017

Absorb BVS: Better Technique, Better Outcomes? More Data—and More Debate

News Conference News CRT 2017

Absorb BVS: Better Technique, Better Outcomes? More Data—and More Debate

Michael O'Riordan

February 21, 2017

DESolve Bioresorbable Stent Compares Well With Absorb but Longer Follow-up Needed

News Daily News

DESolve Bioresorbable Stent Compares Well With Absorb, but Longer Follow-up Needed

Michael O'Riordan

February 16, 2017

Rivaroxaban’s “Overwhelming” Efficacy for Coronary, Peripheral Disease Leads to Early Halt of COMPASS

News Daily News

Rivaroxaban’s ‘Overwhelming’ Efficacy for Coronary, Peripheral Disease Leads to Early Halt of COMPASS

February 08, 2017

News Daily News

Edwards Lifesciences Pauses Transcatheter Mitral Valve Study to Work Out Design Issues

Michael O'Riordan

February 07, 2017

News Daily News

Best Anticoagulant in the TAVR Patient With A-fib? Small Study Makes Case for Apixaban

Michael O'Riordan

January 03, 2017

News Daily News

Not Following NOAC Dosing Instructions Tied to Worse Clinical Outcomes

December 12, 2016

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.